NAD+ Nasal Spray Information & Coordination for Licensed U.S. Clinics
Phoenix Meds Inc. helps licensed U.S. healthcare organizations manage the administrative work involved in connecting with independent licensed pharmacies.
For NAD+ nasal preparation inquiries, Phoenix Meds supports clinic credential verification, documentation organization, publicly available regulatory information, and administrative communication with independent pharmacies.
Phoenix Meds is not a pharmacy, medical practice, manufacturer, prescriber, wholesaler, distributor, or dispensing entity. We do not manufacture, compound, prescribe, dispense, sell, ship, test, or take custody of NAD+ preparations.
What Licensed Clinics Should Know About NAD+ Nasal Preparations
A compounded NAD+ nasal spray is a formulation intended for intranasal administration.
Unlike a standardized commercial drug product, compounded preparations may differ in concentration, excipients, delivery device, packaging, storage requirements, and other formulation details.
Compounded NAD+ nasal preparations are not FDA-approved, and FDA does not review compounded drugs through the same premarket approval process used for FDA-approved drug products.
Phoenix Meds does not make claims that nasal administration provides faster absorption, direct delivery to the brain, greater bioavailability, or improved clinical outcomes.
Current FDA Status and Compounding Considerations
As of FDA’s May 14, 2026 update, Nicotinamide Adenine Dinucleotide (NAD) appears in Category 1 among bulk drug substances still under FDA evaluation for use in compounding under section 503A.
Category 1 status does not mean a compounded NAD+ nasal preparation is FDA-approved or that NAD has been finally added to the 503A Bulks List.
503A and 503B Are Separate Pathways
NAD’s Category 1 status relates specifically to FDA’s 503A framework and does not establish eligibility under section 503B.
Outsourcing facilities operating under 503B are subject to separate requirements governing the bulk drug substances they may use. For clinic coordination purposes, Phoenix Meds keeps these pathways distinct and does not present 503A status as evidence that a preparation qualifies under 503B.
How Phoenix Meds Supports Licensed Clinics
Phoenix Meds provides administrative support for licensed U.S. clinics navigating pharmacy coordination.
For NAD+ nasal preparation inquiries, we can assist with clinic credential verification, organization of available documentation, publicly available regulatory information, and administrative communication with independent pharmacies.
This helps reduce administrative back-and-forth while keeping clinical and pharmaceutical decisions with the licensed parties responsible for them.
Safety and Documentation Considerations
Relevant information may include the formulation and concentration, labeling, storage requirements, dispensing pharmacy information, and any supporting documentation provided with the preparation.
Phoenix Meds can help organize available documentation as part of the administrative coordination process, but we do not independently test or certify a preparation’s purity, potency, sterility, stability, safety, or clinical suitability.
Clinical safety, patient-specific use, and prescribing decisions remain with the appropriately licensed healthcare professionals and pharmacy responsible for patient care.
Administrative Coordination for NAD+ Nasal Preparation Inquiries
Clinic Verification
Before coordination begins, Phoenix Meds reviews professional and facility credentials to confirm that the organization is a licensed healthcare entity.
Documentation Review
Licensed Parties
Frequently Asked Questions
Is compounded NAD+ nasal spray FDA-approved?
No. Compounded drug products are not FDA-approved and do not undergo the same FDA premarket review as approved drug products.
What is NAD’s current 503A status?
As of FDA’s May 14, 2026 update, Nicotinamide Adenine Dinucleotide (NAD) appears in Category 1 of FDA’s materials concerning bulk drug substances nominated for use in compounding under section 503A.
Category 1 means the substance remains under evaluation. It does not mean final inclusion on the 503A Bulks List or FDA approval of a particular compounded preparation.
Does NAD’s 503A Category 1 status also establish eligibility under 503B?
No. Sections 503A and 503B are separate pathways with different requirements.
What can Phoenix Meds help my clinic with?
Phoenix Meds may assist with credential verification, documentation organization, review of publicly available regulatory information, and administrative communication with independent licensed pharmacies.
Important Notice
Phoenix Meds Inc. provides administrative coordination and documentation support for licensed healthcare organizations.
Information on this page is intended for professional purposes. It is not medical advice, a prescribing recommendation, FDA approval, or a determination that a particular compounded preparation is available or appropriate in a specific circumstance.
Regulatory References
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act — Updated May 14, 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act
- Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act
- 503B Bulk Drug Substances List
- GenoGenix LLC — FDA Warning Letter, January 20, 2026
- Consumer and Health Care Professional Information on Compounded Drugs